ESMO - Good science, better medicine, best practice

>>
• Home >
• Meeting Resources >
• Posters >
• 35th ESMO Congress >
• Final results from the ifct-gfpc 0502 phase iii study: maintenance therapy in advanced nsclc with either gemcitabine (g) or erlotinib (e) versus observation (o) after cisplatin-gemcitabine induction chemotherapy (ct), with a predefined second-line tr

Final results from the ifct-gfpc 0502 phase iii study: maintenance therapy in advanced nsclc with either gemcitabine (g) or erlotinib (e) versus observation (o) after cisplatin-gemcitabine induction chemotherapy (ct), with a predefined second-line tr